Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
The advent of immunotherapy has revolutionized cancer treatment. Unfortunately, this has not been the case for metastatic castration-resistant prostate cancer (mCRPC), likely due to the heterogeneous and immune-suppressive microenvironment present in prostate cancer. The identification of molecular...
| Authors: | ; ; ; ; ; ; ; |
|---|---|
| Format: | Article |
| Status: | Published version |
| Publication date: | 2022 |
| Country: | España |
| Institution: | Fundació Sant Joan de Déu |
| Repository: | r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu |
| OAI Identifier: | oai:fsjd.fundanetsuite.com:p22634 |
| Online Access: | https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=22634 |
| Access Level: | Open access |
| Keyword: | immunotherapy metastatic castration-resistant prostate cancer advanced prostate cancer cancer vaccines immune checkpoints inhibitors |
| _version_ | 1878732255103287296 |
|---|---|
| author | Lopez-Campos, F |
| author2 | Gajate, P Romero-Laorden, N Zafra-Martin, J Juan, M Polo, SH Moreno, AC Counago, F |
| author2_role | author author author author author author author |
| author_browse | Counago, F Gajate, P Juan, M Lopez-Campos, F Moreno, AC Polo, SH Romero-Laorden, N Zafra-Martin, J |
| author_facet | Lopez-Campos, F Gajate, P Romero-Laorden, N Zafra-Martin, J Juan, M Polo, SH Moreno, AC Counago, F |
| author_role | author |
| collection | r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu |
| description | The advent of immunotherapy has revolutionized cancer treatment. Unfortunately, this has not been the case for metastatic castration-resistant prostate cancer (mCRPC), likely due to the heterogeneous and immune-suppressive microenvironment present in prostate cancer. The identification of molecular biomarkers that could predict response to immunotherapy represents one of the current challenges in this clinical scenario. The management of advanced castrationresistant prostate cancer is rapidly evolving and immunotherapy treatments, mostly consisting of immune checkpoint inhibitors combinations, BiTE (R) (bispecific T-cell engager) immune therapies, and chimeric antigen receptors (CAR) are in development with promising results. This review analyses the current evidence of immunotherapy treatments for mCRPC, evaluating past failures and promising approaches and discussing the directions for future research. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_3f7c67e4b7a2e8dce6962f7b3095aa8d |
| institution | Fundació Sant Joan de Déu |
| instname_str | Fundació Sant Joan de Déu |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:fsjd.fundanetsuite.com:p22634 |
| publishDate | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI |
| publisherStr | MDPI |
| reponame_str | r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu |
| spelling | Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions Lopez-Campos, F Gajate, P Romero-Laorden, N Zafra-Martin, J Juan, M Polo, SH Moreno, AC Counago, F immunotherapy metastatic castration-resistant prostate cancer advanced prostate cancer cancer vaccines immune checkpoints inhibitors The advent of immunotherapy has revolutionized cancer treatment. Unfortunately, this has not been the case for metastatic castration-resistant prostate cancer (mCRPC), likely due to the heterogeneous and immune-suppressive microenvironment present in prostate cancer. The identification of molecular biomarkers that could predict response to immunotherapy represents one of the current challenges in this clinical scenario. The management of advanced castrationresistant prostate cancer is rapidly evolving and immunotherapy treatments, mostly consisting of immune checkpoint inhibitors combinations, BiTE (R) (bispecific T-cell engager) immune therapies, and chimeric antigen receptors (CAR) are in development with promising results. This review analyses the current evidence of immunotherapy treatments for mCRPC, evaluating past failures and promising approaches and discussing the directions for future research. MDPI https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=22634 |
| spellingShingle | Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions Lopez-Campos, F immunotherapy metastatic castration-resistant prostate cancer advanced prostate cancer cancer vaccines immune checkpoints inhibitors |
| status_str | publishedVersion |
| title | Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions |
| title_full | Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions |
| title_fullStr | Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions |
| title_full_unstemmed | Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions |
| title_short | Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions |
| title_sort | Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions |
| topic | immunotherapy metastatic castration-resistant prostate cancer advanced prostate cancer cancer vaccines immune checkpoints inhibitors |
| topic_facet | immunotherapy metastatic castration-resistant prostate cancer advanced prostate cancer cancer vaccines immune checkpoints inhibitors |
| url | https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=22634 |